Jefferies initiates Credo Technology stock with buy rating on AI growth

Jefferies initiated Credo Technology Group at Buy with a $175 price target, implying 46% upside from $119.59 and using a 23x CY2028 EPS estimate of $7.60. The bullish call cites strong AI-related growth prospects, 68% gross margins, and upward earnings revisions, while noting the stock has already surged more than 208% over the past year. Recent catalysts also include the Robin optical DSP launch and the settlement of patent disputes with TE Connectivity and Molex.

Analysis

CRDO is increasingly a “pick-and-shovel” beneficiary of the AI networking capex cycle, but the second-order trade is that the market is still valuing it like a cyclical component supplier rather than a leverage point on interconnect bottlenecks. If AI cluster density continues to rise, the constraint shifts from compute to bandwidth, latency, and power efficiency, which should support premium pricing for high-speed connectivity even if broader server spend normalizes. That said, the move has already discounted a lot of the obvious upside, so the key question is not demand existence but whether product mix can keep expanding into higher-margin optical content fast enough to sustain multiple expansion.

The patent resolution removes a meaningful overhang, but more importantly it likely improves the company’s ability to engage in design wins without customers pricing in litigation disruption or supply risk. In semis, these settlements often matter less for the headline legal cost than for the reduction in procurement friction: hyperscalers and OEMs prefer suppliers with cleaner IP status when qualifying platforms that will be deployed for 3-5 years. That should help CRDO defend share versus larger interconnect incumbents, though it also raises the bar for execution because competitors can respond through bundled pricing and channel leverage.

Near term, the setup is vulnerable to a “good news, high expectations” reversal over the next 1-3 quarters if earnings revisions stabilize instead of continuing higher. The stock’s outperformance leaves it sensitive to any sign that AI networking demand is lumpy, that optical ramp timing slips, or that gross margin peaks before revenue scale does. The consensus may be underestimating how quickly sentiment can rotate from ‘AI enabler’ to ‘multiple compression’ if bookings growth decelerates even modestly.

The cleanest contrarian angle is that CRDO may still be cheap on 2028 numbers but expensive on the path to those numbers, which is where most equity drawdowns happen. If the market starts to believe 2028 is already embedded, upside becomes dependent on estimate revisions rather than multiple expansion. In that scenario, relative value within AI infrastructure may favor names with nearer-term operating leverage or broader exposure to the capex stack, while CRDO remains the higher-beta expression of the interconnect bottleneck thesis.

Key Decisions for Investors

• Go long CRDO only on pullbacks into the low-$100s or after a 1-2 quarter consolidation; upside remains to multi-bagger territory on 2028 earnings power, but entry matters because the stock already discounts much of the AI narrative.
• Sell covered calls against an existing CRDO position into post-rally strength; use 30-60 day maturities to harvest volatility while capping some upside in a name where expectations can reset quickly.
• Pair trade: long CRDO / short a basket of slower-growth networking hardware peers for 3-6 months; the thesis is that AI interconnect bottlenecks should continue to re-rate best-in-class exposure even if the sector derates.
• If holding CRDO, add a risk trigger: reduce exposure if earnings revisions flatten for one quarter or if the stock loses the prior breakout level on volume, because the downside can be swift once multiple expansion stalls.
• For higher-conviction AI infrastructure exposure, consider using NVDA as a hedge rather than a substitute; CRDO offers more torque to networking spend, but NVDA provides a broader balance against any temporary capex digestion.